MARLBOROUGH, Mass.,
Dec. 18, 2018 /PRNewswire/ -- Phio
Pharmaceuticals Corp. (NASDAQ: PHIO) (formerly RXi
Pharmaceuticals Corporation), a biotechnology company developing
the next generation of immuno-oncology therapeutics based on its
proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform,
announced that Dr. Gerrit Dispersyn, President and Chief Operating
Officer, will present at Biotech Showcase™ 2019, to be held
January 7 – 9, 2019 at the Hilton San
Francisco Union Square.
Logo:
https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. Gerrit Dispersyn will present an overview of the Company's
novel self-delivering RNAi (sd-rxRNA) technology and the multiple
business development and commercial opportunities available with
this proprietary platform on:
Date: Monday, January 7,
2019
Time: 9:00 a.m. PST
Room: Yosemite C (Ballroom Level)
He will also be available for investor and executive meetings
throughout the conference. The presentation will be webcast and
available on the "Investors – Events and Presentations" section of
the Company's website, www.phiopharma.com.
About Biotech Showcase™
Now in its eleventh year,
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an
investor and networking conference devoted to providing private and
public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and executives
in one place during the course of one of the industry's largest
annual healthcare investor conferences, J.P. Morgan Annual
Healthcare Conference.
About Phio Pharmaceuticals Corp.
Phio
Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology
company developing the next generation of immuno-oncology
therapeutics based on its self-delivering RNAi (sd-rxRNA®)
therapeutic platform. The Company's discovery and research efforts
are focused on developing sd-rxRNA therapeutic compounds to be used
in the context of adoptive cell transfer by targeting checkpoints
or other gene targets, or to be used in immunotherapy following
intratumoral injection. We aim to maximize the power of our
sd-rxRNA therapeutic compounds by weaponizing therapeutic immune
effector cells to attack cancer, and to make tumors more
susceptible to such attacks, and ultimately provide patients
battling cancers with a powerful new treatment option that goes
beyond current treatment modalities. For additional
information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are neither historical facts nor assurances of future
performance. These statements are based only on our current
beliefs, expectations and assumptions regarding the future of our
business, future plans and strategies, projections, anticipated
events and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements as a result of a number
of important factors, including, but not limited to, the safety and
efficacy of our product candidates, future success of our clinical
trials and scientific studies, expected duration of available cash
runway, our ability to enter into strategic partnerships and the
future success of these strategic partnerships, the availability of
funds and resources to pursue our research and development projects
and general economic conditions. Our Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q
include detailed risks under the caption "Risk Factors" that may
affect our business, results of operations and financial condition.
Readers are urged to review these risk factors and to not act in
reliance on any forward-looking statements, as actual results may
differ from those contemplated by our forward-looking statements.
Phio does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur
after the date of this release.
Contact
Phio Pharmaceuticals Corp.
ir@phiopharma.com
View original
content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-at-biotech-showcase-2019-in-san-francisco-300767782.html
SOURCE Phio Pharmaceuticals Corp.